{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:13:05Z","timestamp":1788988385500,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100026309","name":"National Marrow Donor Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026309","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["75R60222C00011"],"award-info":[{"award-number":["75R60222C00011"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.04.030","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:10:45Z","timestamp":1776985845000},"page":"1121.e1-1121.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Graft Source on Outcomes of Pediatric B Cell Acute Lymphoblastic Leukemia: A Secondary CIBMTR Analysis With Pretransplant Measurable Residual Disease Data"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-6412","authenticated-orcid":false,"given":"Takuto","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9185-3612","authenticated-orcid":false,"given":"Franziska","family":"Wachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2026.04.030_bib0001","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.030_bib0002","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.030_bib0003","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/OP.21.00843","article-title":"Updates in the management of relapsed and refractory acute lymphoblastic leukemia: an urgent plea for new treatments is being answered!","volume":"18","author":"DuVall","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtct.2026.04.030_bib0004","article-title":"Total body irradiation forever? Optimising chemotherapeutic options for irradiation-free conditioning for paediatric acute lymphoblastic leukaemia","volume":"9","author":"Ben Hassine","year":"2021","journal-title":"Rev Front Pediatr"},{"issue":"21","key":"10.1016\/j.jtct.2026.04.030_bib0005","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.030_bib0006","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/03007995.2017.1384373","article-title":"Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"34","author":"Crotta","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.030_bib0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41409-020-01014-x","article-title":"The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG","volume":"56","author":"Dalle","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.030_bib0008","article-title":"Adverse effects of total body irradiation: a two-decade, single institution analysis","volume":"6","author":"Pearlman","year":"2021","journal-title":"Adv Rad Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.030_bib0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bbmt.2017.09.004","volume":"24","author":"Kelly","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.030_bib0010","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.030_bib0011","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.030_bib0012","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/bloodadvances.2022009253","article-title":"T-cell replete cord transplants give superior outcomes in high-risk and relapsed\/refractory pediatric myeloid malignancy","volume":"7","author":"Horgan","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.030_bib0013","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1182\/bloodadvances.2018025908","article-title":"The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.030_bib0014","doi-asserted-by":"crossref","first-page":"261.e1","DOI":"10.1016\/j.jtct.2025.01.889","article-title":"Umbilical cord blood reduced relapse but increased nonrelapse mortality compared to matched unrelated donor transplantation in pediatric acute myeloid leukemia with active disease: a CIBMTR 2008 to 2017 analysis of donor source and residual disease","volume":"31","author":"Takahashi","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"10.1016\/j.jtct.2026.04.030_bib0015","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2015-06-654780","article-title":"Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells","volume":"126","author":"Hiwarkar","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.030_bib0016","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2020009342","article-title":"A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation","volume":"137","author":"Qayed","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.030_bib0017","doi-asserted-by":"crossref","first-page":"620.e1","DOI":"10.1016\/j.jtct.2021.03.026","article-title":"Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Khimani","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.04.030_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107416","article-title":"A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"135","author":"Ansari","year":"2023","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.030_bib0019","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.jtct.2025.12.162","article-title":"Outcomes of allogeneic stem cell transplantation in the adolescent and young adult population with acute lymphoblastic leukemia based on transplant center: a Center for International Blood and Marrow Transplant Research (CIBMTR) Study","volume":"32","author":"Guerrettaz","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.030_bib0020","doi-asserted-by":"crossref","first-page":"409.e1","DOI":"10.1016\/j.jtct.2022.04.012","article-title":"Updated trends in hematopoietic cell transplantation in the united states with an additional focus on adolescent and young adult transplantation activity and outcomes","volume":"28","author":"Phelan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.030_bib0021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.030_bib0022","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","article-title":"A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission","volume":"12","author":"Marks","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.030_bib0023","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/pbc.25602","article-title":"Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: a study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation","volume":"62","author":"Kato","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.030_bib0024","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1182\/bloodadvances.2023010591","article-title":"Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study","volume":"8","author":"Bader","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.030_bib0025","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.030_bib0026","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.030_bib0027","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy\u2014a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.030_bib0028","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:52:19Z","timestamp":1788987139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003179"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.030","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Graft Source on Outcomes of Pediatric B Cell Acute Lymphoblastic Leukemia: A Secondary CIBMTR Analysis With Pretransplant Measurable Residual Disease Data","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}